Radioligand Therapy (RLT) Market Research Report Information by Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, and Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), and Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, and Others), By End User (Hospitals & Clinics, Diagnostic Centers, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.3. Research Objective

2.4. Assumptions

2.5. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Technique

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE

6.1. Overview

6.2. Fluorine - 18

6.3. Gallium - 68

6.4. Lutetium - 177

6.5. Others

7. GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR

7.1. Overview

7.2. Prostate-specific Membrane Antigen (PSMA)

7.3. Somatostatin Receptor (SSTR)

7.4. Epidermal Growth Factor Receptor (EGFR)

7.5. Others

8. GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION

8.1. Overview

8.2. Prostate Cancer

8.3. Neuroendocrine Tumors (NETs)

8.4. Breast Cancer

8.5. Others

9. GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, BY END USER

9.1. Overview

9.2. Hospitals & Clinics

9.3. Diagnostic Centers

9.4. Others

10. GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, BY REGION

10.1. Overview

10.1. North America

10.1.1. US

10.1.2. Canada

10.2. Europe

10.2.1. Germany

10.2.2. France

10.2.3. UK

10.2.4. Italy

10.2.5. Spain

10.2.6. Rest of Europe

10.3. Asia-Pacific

10.3.1. China

10.3.2. India

10.3.3. Japan

10.3.4. South Korea

10.3.5. Australia

10.3.6. Rest of Asia-Pacific

10.4. Rest of the World

10.4.1. Middle East

10.4.2. Africa

10.4.3. Latin America

11. COMPANY LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Radioligand Therapy (RLT) Market

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Global Radioligand Therapy (RLT) Market

11.7. Key developments and Growth Strategies

11.7.1. New Product Launch

11.7.2. Merger & Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix

11.8.1. Sales & Operating Income, 2022

11.8.2. Major Players R&D Expenditure. 2022

12. COMPANY PROFILES

12.1. Novartis AG

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Products Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. POINT Biopharma Global Inc.

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Products Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Molecular Partners

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Products Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Telix Pharmaceuticals Limited

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Products Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Fusion Pharma

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Products Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Lantheus Holdings, Inc.

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Products Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Curium

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Products Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Precrix

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Products Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Orano Group

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Products Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Artios Pharma

12.10.1. Company Overview

12.10.2. Financial Overview

12.10.3. Products Offered

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, SYNOPSIS, 2019–2030

TABLE 2 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, ESTIMATES & FORECAST, 2019–2030 (USD MILLION)

TABLE 3 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 4 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 5 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 6 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 7 NORTH AMERICA: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 8 NORTH AMERICA: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 9 NORTH AMERICA: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 10 NORTH AMERICA: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 11 US: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 12 US: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 13 US: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 14 US: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 15 CANADA: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 16 CANADA: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 17 CANADA: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 18 CANADA: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 1 EUROPE: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 2 EUROPE: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 3 EUROPE: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 4 EUROPE: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 5 GERMANY: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 6 GERMANY: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 7 GERMANY: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 8 GERMANY: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 9 FRANCE: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 10 FRANCE: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 11 FRANCE: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 12 FRANCE: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 13 ITALY: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 14 ITALY: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 15 ITALY: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 16 ITALY: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 17 SPAIN: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 18 SPAIN: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 19 SPAIN: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 20 SPAIN: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 21 UK: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 22 UK: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 23 UK: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 24 UK: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 25 REST OF EUROPE: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 26 REST OF EUROPE: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 27 REST OF EUROPE: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 28 REST OF EUROPE: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 29 ASIA-PACIFIC: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 30 ASIA-PACIFIC: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 31 ASIA-PACIFIC: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 32 ASIA-PACIFIC: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 33 JAPAN: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 34 JAPAN: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 35 JAPAN: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 36 JAPAN: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 37 CHINA: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 38 CHINA: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 39 CHINA: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 40 CHINA: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 41 INDIA: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 42 INDIA: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 43 INDIA: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 44 INDIA: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 45 AUSTRALIA: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 46 AUSTRALIA: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 47 AUSTRALIA: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 48 AUSTRALIA: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 49 SOUTH KOREA: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 50 SOUTH KOREA: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 51 SOUTH KOREA: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 52 SOUTH KOREA: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 53 REST OF ASIA-PACIFIC: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 54 REST OF ASIA-PACIFIC: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 55 REST OF ASIA-PACIFIC: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 56 REST OF ASIA-PACIFIC: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 57 REST OF THE WORLD: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 58 REST OF THE WORLD: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 59 REST OF THE WORLD: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 60 REST OF THE WORLD: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 61 MIDDLE EAST: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 62 MIDDLE EAST: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 63 MIDDLE EAST: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 64 MIDDLE EAST: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 65 AFRICA: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 66 AFRICA: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 67 AFRICA: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 68 AFRICA: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

TABLE 69 LATIN AMERICA: RADIOLIGAND THERAPY (RLT) MARKET, BY ISOTOPE, 2019–2030 (USD MILLION)

TABLE 70 LATIN AMERICA: RADIOLIGAND THERAPY (RLT) MARKET, BY TARGETED RECEPTOR, 2019–2030 (USD MILLION)

TABLE 71 LATIN AMERICA: RADIOLIGAND THERAPY (RLT) MARKET, BY INDICATION, 2019–2030 (USD MILLION)

TABLE 72 LATIN AMERICA: RADIOLIGAND THERAPY (RLT) MARKET, BY END USER, 2019–2030 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL RADIOLIGAND THERAPY (RLT) MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL RADIOLIGAND THERAPY (RLT) MARKET

FIGURE 4 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, SHARE (%), BY ISOTOPE, 2022

FIGURE 5 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, SHARE (%), BY TARGETED RECEPTOR, 2022

FIGURE 6 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, SHARE (%), BY INDICATION, 2022

FIGURE 7 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, SHARE (%), BY END USER, 2022

FIGURE 8 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 NORTH AMERICA: RADIOLIGAND THERAPY (RLT) MARKET, SHARE (%), BY COUNTRY, 2022

FIGURE 10 EUROPE: RADIOLIGAND THERAPY (RLT) MARKET, SHARE (%), BY COUNTRY, 2022

FIGURE 11 ASIA-PACIFIC: RADIOLIGAND THERAPY (RLT) MARKET, SHARE (%), BY COUNTRY, 2022

FIGURE 12 REST OF THE WORLD: RADIOLIGAND THERAPY (RLT) MARKET, SHARE (%), BY REGION, 2022

FIGURE 13 GLOBAL RADIOLIGAND THERAPY (RLT) MARKET: COMPANY SHARE ANALYSIS (%), 2022

FIGURE 14 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 NOVARTIS AG: SWOT ANALYSIS

FIGURE 16 POINT BIOPHARMA GLOBAL INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 POINT BIOPHARMA GLOBAL INC.: SWOT ANALYSIS

FIGURE 18 MOLECULAR PARTNERS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 MOLECULAR PARTNERS: SWOT ANALYSIS

FIGURE 20 TELIX PHARMACEUTICALS LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 TELIX PHARMACEUTICALS LIMITED: SWOT ANALYSIS

FIGURE 22 FUSION PHARMA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 FUSION PHARMA: SWOT ANALYSIS

FIGURE 24 LANTHEUS HOLDINGS, INC.: FINANCIAL OVERVIEW SNAPSHOT